Cryoport, Inc. (CYRX)
Today, CYRX has shed (-10.00%) down -0.050 at $.450 with�179,695 shares in play thus far (ref. google finance Delayed: 12:35PM EDT October 4, 2013).
Cryoport, Inc. and OCASA, Inc. have previously entered into a master services agreement to provide global cold chain logistics solutions for life science and biotech commodities requiring cryogenic temperatures. OCASA will have access to Cryoport�� full range of cryogenic business solution capabilities including its proprietary Cryoport Express庐 Shippers and cloud-based logistics management software platform, the CryoportalTM. Cryoport will leverage OCASA�� global logistics network to provide more complete global services to its customers. In conjunction with Cryoport and OCASA providing each other with logistics solutions, the Companies will engage in co-marketing, joint sales activities, and a wide range of customer-driven support requirements to provide comprehensive and seamless solutions to the life sciences and biotech industries
Hot Logistics Stocks For 2015: Escalade Incorporated (ESCA)
Escalade, Incorporated engages in the manufacture and sale of sporting goods, and information security and print finishing products worldwide. It operates in two segments, Sporting Goods, and Information Security and Print Finishing. The Sporting Goods segment manufactures, imports, and distributes family recreation, fitness, training, and hunting products. It offers archery products under the Bear Archery, Trophy Ridge, and Whisker Biscuit brands; table tennis under the STIGA and Ping-Pong brands; basketball backboards and goals under the Goalrilla, Goaliath, and Silverback brands; play systems under the Woodplay and Childlife brands; fitness products under The STEP and USWeight brands; hockey and soccer game tables under the Harvard Game, Atomic, and Accudart brands; and pool tables and accessories under the Mosconi and Mizerak brands. This segment offers its products through traditional department stores, mass merchandise retailers, and sporting goods specific retailers . The Information Security and Print Finishing segment offers shredders, disintegrators, degaussers, paper folders, letter openers, and paper cutters/trimmers under the martin yale, intimus, and papermonster brands. It offers products and services directly to end-users, as well as through retailers, wholesalers, catalogs, specialty dealers, and business partners. This segment focuses on corporate customers, governments, and strategic business partners. Escalade, Incorporated was founded in 1922 and is headquartered in Evansville, Indiana.
Advisors' Opinion: Hot Logistics Stocks For 2015: Move Inc.(MOVE)
Move, Inc., together with its subsidiaries, operates an online network of Websites for real estate search, finance, and moving and home enthusiasts in North America. The company operates REALTOR.com, a Web site that offers property listings and neighborhood profiles; and consumers information and tools designed to assist the customers in understanding the value of their home, preparing the home for sale, listing and advertising the home, home affordability, the offer process, applying for a loan, understand the mortgage options available, closing the purchase, and planning the move. REALTOR.com provides showcase listing enhancements; display ad products; and a series of template Websites primarily for agents and brokers. The company also offers 8i solution, a Web-based customer relationship management software application for real estate agents. In addition, it provides Market Snapshot and Market Builder products that allow real estate professionals to offer real-time mult iple listing services market updates and trend analysis to their online prospects and clients; and Move Rentals that displays rental listings. Further, the company provides graphical display advertisements, text links, sponsorships, and directories for advertisers for mortgage companies, home improvement retailers, moving service providers, and other consumer product and service companies. Additionally, it offers quotes from moving companies, truck rental companies, and self-storage facilities, as well as other move-related information on Moving.com Website. Move, Inc. also operates as an online real estate listing syndicator and provider of performance reporting solutions for the purpose of helping to drive an online advertising program for brokers, real estate franchises, and individual agents. The company was formerly known as Homestore, Inc. and changed its name to Move, Inc. in June 2006. Move, Inc. was founded in 1993 and is headquartered in Westlake Village, Californi a.
Advisors' Opinion: - [By John Udovich]
Small cap online real estate listings stock Trulia Inc (NYSE: TRLA)�jumped 8.52%�yesterday and has doubled since the start of the year, but insiders have been selling -�meaning its time to take a closer look at the stock along with the performance of peers like Zillow Inc (NASDAQ: Z) and Move Inc (NASDAQ: MOVE). So what should outside investors do with Trulia Inc?
- [By Roberto Pedone]
Move (MOVE) operates an online network of Web sites for real estate search, finance and moving and home enthusiasts in North America. This stock closed up 2.6% at $14.96 in Monday's trading session.
Monday's Volume: 879,000
Three-Month Average Volume: 649,437
Volume % Change: 50%
From a technical perspective, MOVE jumped notably higher here right above its 200-day moving average of $14.05 with above-average volume. This spike higher on Monday is starting to push shares of MOVE within range of triggering a major breakout trade. That trade will hit if MOVE manages to take out some key near-term overhead resistance levels at Monday's intraday high of $15.07 to $15.46 with high volume.
Traders should now look for long-biased trades in MOVE as long as it's trending above its 200-day at $14.05 or above more near-term support at $13.50 and then once it sustains a move or close above those breakout levels with volume that's near or above 649,437 shares. If that breakout triggers soon, then MOVE will set up to re-test or possibly take out its next major overhead resistance levels at $17 to $18, or even its 52-week high at $18.36.
Top 5 Promising Companies To Buy Right Now: Six Flags Entertainment Corporation New(SIX)
Six Flags Entertainment Corporation owns and operates regional theme, water, and zoological parks. The company?s parks offers various selection of state-of-the-art and traditional thrill rides, water attractions, themed areas, concerts and shows, restaurants, game venues, and retail outlets. It owns and operates 19 parks, including 17 parks in the United States; 1 park in Mexico City, Mexico; and 1 park in Montreal, Canada. The company was formerly known as Six Flags, Inc. and changed its name to Six Flags Entertainment Corporation in April 2010. Six Flags Entertainment Corporation was founded in 1971 and is based in Grand Prairie, Texas.
Advisors' Opinion: - [By Rick Munarriz]
Our timing couldn't have been better. Despite the ridiculous heat wave, Six Flags (NYSE: SIX ) had just opened a new coaster -- Full Throttle -- at Magic Mountain just a few days earlier.
- [By Jacob Steinberg]
Walt Disney's theme parks and cruise ships are seeing incredibly strong demand across the world. In the last couple years, the global economy hasn't been very strong. However, Disney's theme parks continued to increase their volume and spending-per-customer significantly during this period. This year, the company increased its admission ticket prices but this didn't affect the demand at all, which shows that most of Disney's theme park customers don't even care how much they are spending at these parks. This is very bullish for the company. In fact, Six Flags (SIX) also reported seeing strong numbers this year, which tells me that the bullishness in the theme park business will be here to stay.
- [By WWW.DAILYFINANCE.COM]
www.sixflags.com Summer is the peak season for enjoying thrill rides and family-friendly attractions at amusement and theme parks. Summer may also be a good time to approach these havens of coasters and cotton candy as investing ideas. Let's go over a few reasons why the fundamentals are strong for the industry. 1. Big Thrills Add Up to Big Yields Six Flags (SIX) and Cedar Fair (FUN) -- the country's two largest regional amusement park operators -- combined to entertain 49.6 million guests last year, and 80 percent of those visits came between Memorial Day and Labor Day. Many publicly traded amusement park operators pay out hefty quarterly distributions. Cedar Fair can get the credit for that pocket-happy trend. It's organized as a limited partnership, distributing most of its income to its stakeholders. Cedar Fair units currently yield 5.3 percent. When Six Flags returned as a public company four years ago, it decided to also declare beefy dividends. It now yields a healthy 4.5 percent. Even marine life park operator SeaWorld (SEAS) decided to ride the wave when it went public in last year. Its stock packs a 2.8 percent yield. Leading theme park operators Disney (DIS) and Universal Studios parent Comcast (CMCSK) aren't as generous with their payouts, with yields of 1 percent and 1.7 percent, respectively. 2. Parks are Making Big Investments for the Future Gated attractions aren't hesitating to make big investments that will pay off in the coming years. Just a few days ago, Indiana's Holiday World announced that it will spend $22 million for an ambitious expansion next summer that includes the country's first launched wing coaster. If a small yet critically acclaimed family-owned park can justify that kind of investment, one can only imagine what the larger operators will do. Universal Orlando has made a nine-figure investment this summer in its bar-raising Diagon Alley expansion. Despite some operating hiccups with the Harry Potter-themed area's flagshi
- [By John Kell]
Six Flags Entertainment Corp.(SIX) said its fourth-quarter revenue rose more than expected on higher admissions and an increase in in-park spending, sponsorships and accommodations. Shares edged up 3.3% to $39.50 premarket.
Hot Logistics Stocks For 2015: Forest Laboratories Inc (FRX)
Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.
Aclidinium
In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Linaclotide
Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.
Viibryd
As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.
Daliresp
In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Namenda
Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.
Bystolic
Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).
Savella
Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.
Teflaro
In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.
Avibactam
Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.
Lexapro
Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.
Cariprazine
Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.
Levomilnacipran
Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.
GRT 6005
In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.
TTP399
In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.
Azimilide
In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.
RGH-618
RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.
Advisors' Opinion: - [By Jon C. Ogg]
Forest Laboratories Inc. (NYSE: FRX) is already closing on one deal, and was shown as having 3 deals under its belt in the last ten years. The Merrill Lynch report here shows that its focus is on primary care products within its current five therapeutic areas: GI, cardiovascular, CNS, respiratory, and infectious disease. They show that Forest is open to deals to replenish the drug pipeline with a high probability of success. Forest is worth more than $17 billion.
- [By Johanna Bennett]
Forest Laboratories (FRX) surged 9.7% to close at $56.32, marking the biggest gain in the S&P 500. The drug maker unveiled plans to trim $500 million in costs, and spend at least $400 million buying back its stock.
- [By Sean Williams]
Believe it or not, Forest Laboratories (NYSE: FRX ) continued its string of good news following word from the Food and Drug Administration on Friday that Fetzima, a drug co-developed with Pierre Fabre Laboratories, had been approved to treat major depressive disorder. This is a big step for Forest Labs, which lost MDD drug Lexapro to patent expiration last year and now could be set to capitalize on a disease that can affect as many as 15 million people in the U.S. -- all with Eli Lilly's�Cymbalta, a $5 billion-a-year drug, set to lose patent protection itself in the fourth quarter.
Hot Logistics Stocks For 2015: AllianceBernstein Income Fund Inc (ACG)
AllianceBernstein Income Fund Inc. (the Fund), formerly known as ACM Income Fund Inc., is a diversified closed-end management investment company. The Fund's investment objective is to provide high current income consistent with the preservation of capital. The Fund normally invests at least 80% of its net assets in income producing securities. It normally invests at least 65% of its assets in securities issued or guaranteed by the United States Government, its agencies or instrumentalities, and repurchase agreements pertaining to the United States Government securities. It may also invest up to 35% of its assets in other fixed-income securities, including those issued by non-governmental issuers in the United States and those issued by foreign governments. The Fund may invest up to 35% of its net assets in below-investment-grade securities. In addition, the Fund may utilize other investment instruments, including options and futures, and may employ leverage. On January 26, 2007, AllianceBernstein Income Fund Inc. acquired ACM Government Opportunity Fund, Inc.
The Fund invests in sovereign debt obligations of countries that are considered emerging market countries at the time of purchase. Part of the Fund's assets will be invested in foreign securities. AllianceBernstein Income Fund Inc.�� investment advisor is AllianceBernstein L.P. (formerly known as Alliance Capital Management L.P.).
Advisors' Opinion: - [By Harry Domash, Publisher, DividendDetective and Winning Investing]
For instance, AllianceBernstein Income, ticker (ACG), has about 70% of its holdings rated AAA, which is the highest rating you can get. We have some that invest in global real estate.
We have some invested in utility, preferreds, and common. We have some invested in emerging market debt. We try to cover the whole spectrum of investing. When you're looking at monthly payers, you're usually getting bond funds as opposed to stock funds.
Steven Halpern: Now among those closed-end funds is there a name or two that stands out that people should be looking at?
Harry Domash: Well, one that's really good for us has been Reaves Utility Income. It holds primarily US utility and telecom stocks and it's been a pretty good dividend raiser. The ticker is (UTG), paying about a 6.1% yield now and it's a good serial dividend increaser so it's a very good one.
If you're worried about rising interest rates then Invesco Dynamic Credit Opportunities, ticker (VTA), invests in below investment-grade floating rate bank loans. In other words, these are called senior loans.
They're bank loans that adjust their payouts based on prevailing interest rates, so if interest rates go up, these loans will pay higher dividends, so this is a good hedge if you are concerned about rising interest rates.
Another one that's really performed, and it's paying a 6.9% yield right now, Guggenheim Strategic Opportunities, ticker (GOF), that's actually Claymore Guggenheim, holds corporate and government backed, that it's mostly investment-grade and it's paying a 10.1% yield right now, which is pretty high. Those are three that I could recommend right now.
Steven Halpern: Well, we really appreciate you joining us today and sharing your expertise. Thank you.
Harry Domash: You're welcome.
Subscribe to the Dividend Detective here...
Hot Logistics Stocks For 2015: Spartan Stores Inc.(SPTN)
Spartan Stores, Inc. operates as a grocery distributor and retailer principally in Michigan and Indiana. The company operates in two segments, Distribution and Retail. The Distribution segment provides approximately 43,000 stock-keeping units, including dry groceries, produce, dairy products, meat, deli, bakery, frozen food, seafood, floral products, general merchandise, pharmacy, and health and beauty care items to approximately 375 independent grocery stores and 96 corporate-owned stores, as well as offers approximately 3,600 private brand grocery and general merchandise items. It also provides value-added services, including site identification and market analyses; store planning and development; marketing, promotion, advertising; technology and information; accounting and tax preparation; human resource; coupon redemption; product reclamation; printing; category management; real estate; and construction management services. The Retail segment operates 97 retail superma rkets in Michigan under the Glen?s Markets, Family Fare Supermarkets, D&W Fresh Markets, VG?s Food and Pharmacy, and Valu Land names; and 25 fuel centers/convenience stores that offers refueling facilities, as well as immediately consumable products under the Glen?s Quick Stop, Family Fare Quick Stop, D&W Fresh Markets Quick Stop, and VG?s Quick Stop names. Its retail supermarkets offer dry groceries, produce, dairy products, meat, frozen food, seafood, floral products, general merchandise, beverages, tobacco products, health and beauty care products, delicatessen items, and bakery goods, as well as pharmacy services. This segment also provides private brand items, including its Spartan brand; Fresh Selections; Top Care, a health and beauty care brand; Valu Time, a value brand; Full Circle, a natural and organic brand; and Paws, a pet supplies brand. The company was founded in 1917 and is headquartered in Grand Rapids, Michigan.
Advisors' Opinion: - [By Jeremy Bowman]
What: Shares of Nash-Finch (NASDAQ: NAFC ) and Spartan Stores (NASDAQ: SPTN ) jumped as much as 16% and 15%, respectively, after Spartan said it would buy Nash-Finch, primarily for its military stores.
- [By GURUFOCUS]
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number
SYY is trading at a premium to all four valuations above. The stock is trading at a 37.5% premium to its calculated fair value of $26.26. SYY did not earn any Stars in this section.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%
SYY earned two Stars in this section for 2.) and 3.) above. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. SYY earned a Star for having an acceptable score in at least two of the four Key Metrics measured. The company has paid a cash dividend to shareholders every year since 1970 and has increased its dividend payments for 43 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description:
1. NPV MMA Diff.
2. Years to > MMA
The NPV MMA Diff. of the $282 is below the $500 target I look for in a stock that has increased dividends as long as SYY has. If SYY grows its dividend at 3.6% per year, it will take 3 years to equal a MMA yielding an estimated 20-year average rate of 3.41%. SYY earned a check for the Key Metric 'Years to >MMA' since its 3 years is le
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Spartan Stores (Nasdaq: SPTN ) , whose recent revenue and earnings are plotted below.
- [By Seth Jayson]
Margins matter. The more Spartan Stores (Nasdaq: SPTN ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Spartan Stores's competitive position could be.
Hot Logistics Stocks For 2015: Winnebago Industries Inc.(WGO)
Winnebago Industries, Inc. manufactures and sells recreation vehicles primarily for leisure travel and outdoor recreation activities. The company offers motor homes, which are self-propelled mobile dwellings that provide living accommodations for approximately seven persons and include kitchen, dining, sleeping, and bath areas, as well as a lounge; and optional equipment accessories, such as generators, home theater systems, king-size beds, upholstery, and interior equipment. It manufactures motor homes constructed directly on medium- and heavy-duty truck chassis, which include engine and drivetrain components; and on van-type chassis onto which the motor home manufacturer constructs a living area with access to the driver's compartment under the Winnebago and Itasca brand names, as well as panel-type vans with sleeping, kitchen, and/or toilet facilities under the Era brand name. The company also produces original equipment manufacturing parts, including extruded aluminum and other component products for other manufacturers and commercial vehicles. Winnebago Industries markets its motor homes through independent dealers primarily in the United States and Canada. The company was founded in 1958 and is headquartered in Forest City, Iowa.
Advisors' Opinion: - [By Grace L. Williams]
Recreational vehicle maker Winnebago Industries (WGO), which makes, you know, Winnebagos, is trucking today after reporting strong revenue and increased demand in its fourth quarter.
AP For the period ended Aug. 31, Winnebago reported profit of $10.6 million, or 38 cents a share, down from $40.9 million, or $1.41 a share, a year earlier, while sales rose to $214.2 million in the quarter. Analysts polled by Thomson Reuters recently predicted earnings of 28 cents a share and sales of $206 million.
Looking at the solid quarter and optimistic forecasts, Citigroup analyst Gregory Badishkanian raised estimates after noting several positive factors at the company including the current backlogs, which more than doubled, and dealer inventories, which were up 38%. He writes:
The company highlighted two issues that appear to be diminishing: 1) towables division was dilutive for the year, but headed in the right direction with a breakeven quarter 2) shortage in Class A Gas chassis, though the issue should be resolved by mid-winter…
Given strong margin and retail demand trends, we��e raising our 2014 and 2015 estimates by 26 cents each. We introduce our 2016 estimate of $ 1.60.
Shares of Winnebago have gained 4.4% to $28.47 today at 3pm. Thor Industries (THO), which also makes recreational vehicles, has ticked up 0.1% to $57.56, Drew Industries (DW) has risen 0.3% to $48.74, Arctic Cat (ACAT) has advanced 1% to $59.87 and Polaris Industries (PII) has fallen 0.3% to $132.08.
- [By Jack Kramer and Nick Martell]
2. Winnebago sales surged last quarter
If the van is a-rockin', investors come a-knockin'. That's the basic premise behind the recent performance of Winnebago (NYSE: WGO ) , the recreational-vehicle giant that all good nature-loving rural Americans love. The stock rose 3.6% Monday after reporting $247.7 million in quarterly revenue, a 13.5% jump from the same period last year.
- [By John Udovich]
The CEO of recreation vehicle (RV) stock Winnebago Industries, Inc (NYSE: WGO) recently appeared on CNBC to say that the economy is improving for RV makers, meaning its time to take a closer look at the stock plus take a look at the performance of other small cap RV stocks like Drew Industries, Inc (NYSE: DW), Skyline Corporation (NYSEMKT: SKY) and Thor Industries, Inc (NYSE: THO).
